On July 24, 2023, Quince Therapeutics, Inc. announced the departure of Karen Smith, M.D., Ph.D., the Company?s Chief Medical Officer, effective as of September 1, 2023 (the Departure Date).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.922 USD | -2.95% | -6.10% | -14.15% |
01/04 | Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
26/03 | Transcript : Quince Therapeutics, Inc. - Special Call |
1st Jan change | Capi. | |
---|---|---|
-14.15% | 41.05M | |
+27.48% | 44.96B | |
-0.24% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+10.04% | 26.08B | |
-21.11% | 19.03B | |
+6.23% | 12.75B | |
+28.72% | 12.06B | |
-3.47% | 11.75B |
- Stock Market
- Equities
- QNCX Stock
- News Quince Therapeutics, Inc.
- Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023